



CLS receives market approval for its TRANBERG portfolio by HSA in Singapore and initiates the process of commercialization in the region

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) today announces that the company has received market approval for its entire portfolio of TRANBERG® Thermal Therapy products in Singapore for thermal ablation of soft tissue pathological lesions for tumor control, symptomatic relief and restoring of physiological functions in the prostate and liver.

The market approval for CLS portfolio of TRANBERG Thermal Therapy Systems by HSA in Singapore constitutes a significant milestone in the company's global expansion and enables CLS to initiate the process of commercialization throughout the Singapore market. In addition, the approval, combined with early successful treatment outcomes, allows for a wider commercialization in the Asia-Pacific region. The commercial start in Singapore & expansion into the Asia-Pacific region is being carried out through CLS joint venture CLS Asia Pacific PTE. LTD headquartered in the Republic of Singapore.

"This is a long-awaited breakthrough that we have been working hard to achieve over a long period of time. The Asia-Pacific region is a populous region, with increasing medical needs, where our TRANBERG portfolio for minimal invasive focal laser ablation can provide great value for patients & therapy providers. Through CLS Asia Pacific we have already established clinical relationships in the region and now intend to deepen these and initiate commercialization of our product portfolio, starting within the growing field of focal therapy for treatment of patients with low to mid grade localized prostate cancer," says Dan J. Mogren, CEO, CLS.

The TRANBERG Thermal Therapy System now enters into a limited market release at selected medical centers across Singapore. Full indications for use can be found here: [Public Enquiry - Singapore Medical Device Register \(SMDR\) \(hsa.gov.sg\)](https://www.hsa.gov.sg/public-enquiry-smdr)

Contact Information:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 705 90 11 40

E-mail: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal

effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se